On the path of better ways to treat prostate cancer

May 16, 2014, Monash University
On the path of better ways to treat prostate cancer
Professor Gail Risbridger

(Medical Xpress)—Improved screening means doctors are more likely to detect prostate cancer in time to treat it, but knowing when that treatment will be necessary is still uncertain.

Prostate cancer develops in two distinct ways. In one form, it is a slow-growing cancer that affects one in nine overall or one in five men aged 85 or older, and which can be treated if detected early. The other form looks just like its twin, but is aggressive, becomes resistant to treatment, spreads rapidly and eventually kills the patient.

Professor Mark Frydenberg, expert in urology in the Department of Surgery at Monash University, said the difference affected decisions about treatment.

"If you diagnose a man with what appears to be low-risk , how certain can we be that this is not going to progress and become life-threatening and how safe is it for us to just keep an eye on it rather than immediately treat it?" Professor Frydenberg said.

"If we operate on everybody, we're subjecting a lot of men to unnecessary side effects from surgery that they may not have needed."

A major clue in the quest to identify men at risk of progressing to advanced disease, and prevent that from occurring, has been found by the team of Professor Gail Risbridger, head of the Prostate Cancer Research Group at Monash.

Professor Risbridger has identified a subset of that are resistant to androgen deprivation treatment, used for advanced prostate cancer. These cells share many features with and may be present at early stages of the disease.

"This tells us the cells are plastic and can adapt and survive treatments such as castration or androgen withdrawal to regenerate a tumour," Professor Risbridger said of the discovery, published last year in the journal Science Translational Medicine.

"We already know a lethal sub-population of cells will kill a man when the disease is advanced. Now we can see cells with these features much earlier in men when the disease is still localised, so we have the opportunity to use this insight to understand how localised disease progresses to advanced disease."

While the existence of these might be seen as bad news, Professor Risbridger said that knowledge of them provided the opportunity to develop new treatments that would target them.

Explore further: New possibilities for prostate cancer treatment revealed

Related Stories

New possibilities for prostate cancer treatment revealed

May 29, 2013
Researchers have identified a sub-group of cells that could contribute to prostate cancer recurrence, opening up new ways to treat the disease, which claims more than 3000 lives a year in Australia.

Scientists overcome barrier to prostate cancer research

October 24, 2013
Monash scientists have overcome one of the major barriers to the study and treatment of localised -or organ confined- prostate cancer.

Study finds prostate cancer tests underestimate disease in half of cases

April 11, 2014
A study published in the British Journal of Cancer suggests that tests to grade and stage prostate cancer underestimated the severity of the disease in half of men whose cancers had been classified as 'slow growing'.

Primary androgen deprivation therapy ineffective for most men with early prostate cancer

March 17, 2014
A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received ...

Older, sicker men with early-stage prostate cancer do not benefit from aggressive treatment

May 13, 2014
Treating older men with early-stage prostate cancer who also have other serious underlying health problems with aggressive therapies such as surgery or radiation therapy does not help them live longer and, in fact, can be ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.